324 related articles for article (PubMed ID: 34037224)
1. Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study.
Sakai H; Morise M; Kato T; Matsumoto S; Sakamoto T; Kumagai T; Tokito T; Atagi S; Kozuki T; Tanaka H; Chikamori K; Shinagawa N; Takeoka H; Bruns R; Straub J; Schumacher KM; Paik PK
Jpn J Clin Oncol; 2021 Aug; 51(8):1261-1268. PubMed ID: 34037224
[TBL] [Abstract][Full Text] [Related]
2. Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.
Morise M; Kato T; Matsumoto S; Inoue T; Sakamoto T; Tokito T; Atagi S; Kozuki T; Takeoka H; Chikamori K; Shinagawa N; Tanaka H; Horii E; Adrian S; Bruns R; Johne A; Paik PK; Sakai H
Cancer Sci; 2024 Apr; 115(4):1296-1305. PubMed ID: 38402853
[TBL] [Abstract][Full Text] [Related]
3. Tepotinib in Non-Small-Cell Lung Cancer with
Paik PK; Felip E; Veillon R; Sakai H; Cortot AB; Garassino MC; Mazieres J; Viteri S; Senellart H; Van Meerbeeck J; Raskin J; Reinmuth N; Conte P; Kowalski D; Cho BC; Patel JD; Horn L; Griesinger F; Han JY; Kim YC; Chang GC; Tsai CL; Yang JC; Chen YM; Smit EF; van der Wekken AJ; Kato T; Juraeva D; Stroh C; Bruns R; Straub J; Johne A; Scheele J; Heymach JV; Le X
N Engl J Med; 2020 Sep; 383(10):931-943. PubMed ID: 32469185
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION.
Kato T; Yang JC; Ahn MJ; Sakai H; Morise M; Chen YM; Han JY; Yang JJ; Zhao J; Hsia TC; Berghoff K; Bruns R; Vioix H; Lang S; Johne A; Le X; Paik PK
Br J Cancer; 2024 Jun; 130(10):1679-1686. PubMed ID: 38575731
[TBL] [Abstract][Full Text] [Related]
5. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC;
Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794
[TBL] [Abstract][Full Text] [Related]
6. Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial.
Mazieres J; Paik PK; Garassino MC; Le X; Sakai H; Veillon R; Smit EF; Cortot AB; Raskin J; Viteri S; Wu YL; Yang JCH; Ahn MJ; Ma R; Zhao J; O'Brate A; Berghoff K; Bruns R; Otto G; Johne A; Felip E; Thomas M
JAMA Oncol; 2023 Sep; 9(9):1260-1266. PubMed ID: 37270698
[TBL] [Abstract][Full Text] [Related]
7. FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations.
Mathieu LN; Larkins E; Akinboro O; Roy P; Amatya AK; Fiero MH; Mishra-Kalyani PS; Helms WS; Myers CE; Skinner AM; Aungst S; Jin R; Zhao H; Xia H; Zirkelbach JF; Bi Y; Li Y; Liu J; Grimstein M; Zhang X; Woods S; Reece K; Abukhdeir AM; Ghosh S; Philip R; Tang S; Goldberg KB; Pazdur R; Beaver JA; Singh H
Clin Cancer Res; 2022 Jan; 28(2):249-254. PubMed ID: 34344795
[TBL] [Abstract][Full Text] [Related]
8. Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice.
Le X; Sakai H; Felip E; Veillon R; Garassino MC; Raskin J; Cortot AB; Viteri S; Mazieres J; Smit EF; Thomas M; Iams WT; Cho BC; Kim HR; Yang JC; Chen YM; Patel JD; Bestvina CM; Park K; Griesinger F; Johnson M; Gottfried M; Britschgi C; Heymach J; Sikoglu E; Berghoff K; Schumacher KM; Bruns R; Otto G; Paik PK
Clin Cancer Res; 2022 Mar; 28(6):1117-1126. PubMed ID: 34789481
[TBL] [Abstract][Full Text] [Related]
9. Matching-Adjusted Indirect Comparison (MAIC) of Tepotinib with Other MET Inhibitors for the Treatment of Advanced NSCLC with MET Exon 14 Skipping Mutations.
Paik PK; Pfeiffer BM; Vioix H; Garcia A; Postma MJ
Adv Ther; 2022 Jul; 39(7):3159-3179. PubMed ID: 35543963
[TBL] [Abstract][Full Text] [Related]
10. Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation.
Tanaka H; Taima K; Makiguchi T; Nakagawa J; Niioka T; Tasaka S
Cancer Commun (Lond); 2021 Jan; 41(1):83-87. PubMed ID: 33387444
[TBL] [Abstract][Full Text] [Related]
11. Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management.
Veillon R; Sakai H; Le X; Felip E; Cortot AB; Smit EF; Park K; Griesinger F; Britschgi C; Wu YL; Melosky B; Baijal S; Jr GC; Sedova M; Berghoff K; Otto G; Paik PK
Clin Lung Cancer; 2022 Jun; 23(4):320-332. PubMed ID: 35466070
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
Drusbosky LM; Dawar R; Rodriguez E; Ikpeazu CV
J Hematol Oncol; 2021 Aug; 14(1):129. PubMed ID: 34425853
[TBL] [Abstract][Full Text] [Related]
13. Capmatinib in Japanese patients with MET exon 14 skipping-mutated or MET-amplified advanced NSCLC: GEOMETRY mono-1 study.
Seto T; Ohashi K; Sugawara S; Nishio M; Takeda M; Aoe K; Moizumi S; Nomura S; Tajima T; Hida T
Cancer Sci; 2021 Apr; 112(4):1556-1566. PubMed ID: 33506571
[TBL] [Abstract][Full Text] [Related]
14. Tepotinib hydrochloride for the treatment of non-small cell lung cancer.
Wu ZX; Li J; Dong S; Lin L; Zou C; Chen ZS
Drugs Today (Barc); 2021 Apr; 57(4):265-275. PubMed ID: 33851690
[TBL] [Abstract][Full Text] [Related]
15. Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation.
Takamori S; Matsubara T; Fujishita T; Ito K; Toyozawa R; Seto T; Yamaguchi M; Okamoto T
Thorac Cancer; 2021 Mar; 12(6):978-980. PubMed ID: 33533182
[TBL] [Abstract][Full Text] [Related]
16. Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations.
Xiong W; Hietala SF; Nyberg J; Papasouliotis O; Johne A; Berghoff K; Goteti K; Dong J; Girard P; Venkatakrishnan K; Strotmann R
Cancer Chemother Pharmacol; 2022 Jul; 90(1):53-69. PubMed ID: 35771259
[TBL] [Abstract][Full Text] [Related]
17. Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report.
Tseng LW; Chang JW; Wu CE
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233109
[TBL] [Abstract][Full Text] [Related]
18. Tepotinib: Management of Adverse Events in Patients With MET Exon 14 Skipping Non-Small Cell Lung Cancer.
Ahn L; Alexander T; Vlassak S; Berghoff K; Lemmens L
Clin J Oncol Nurs; 2022 Sep; 26(5):543-551. PubMed ID: 36108212
[TBL] [Abstract][Full Text] [Related]
19. Absence of cross-toxicity between MET inhibitors in a non-small-cell lung cancer with a MET exon 14 skipping mutation.
Vanderick A; Colinet B
Acta Clin Belg; 2024 Apr; 79(2):148-151. PubMed ID: 38494868
[TBL] [Abstract][Full Text] [Related]
20. Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring METex14 Skipping in the UK.
Batteson R; Hook E; Wheat H; Hatswell AJ; Vioix H; McLean T; Alexopoulos ST; Baijal S; Paik PK
Target Oncol; 2024 Mar; 19(2):191-201. PubMed ID: 38492157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]